EGFR and esophageal squamous cell carcinoma: Experiments using AG1478, an EGFR tyrosine kinase inhibitor known to suppress pEGFR (Tyr1068) [44], demonstrated that the EGFR-Erk/p38 MAPK signaling pathway plays a critical role in the malignant phenotypes of ESCC cells.